Form 4: Clene CSO Mark Mortenson Granted 10,000 Stock Options

Clene Inc.'s Chief Science Officer, Mark Mortenson, received a grant of 10,000 stock options with an exercise price of $6.32 per share, vesting immediately.

Summary

• Mark Mortenson, Chief Science Officer of Clene Inc. (CLNN), was granted 10,000 stock options.
• The options were granted on September 18, 2025, under the Clene Inc. Amended 2020 Stock Plan.
• Each option has an exercise price of $6.32 per share.
• The options vest immediately upon grant.
• The expiration date for these options is September 17, 2035.
• Following this transaction, Mr. Mortenson beneficially owns 10,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a positive signal for management alignment and retention, though it is a routine compensation event and not a significant market catalyst.

Positives

• The grant of stock options aligns the Chief Science Officer's interests with those of shareholders, incentivizing long-term company performance.
• Immediate vesting of the options provides immediate equity exposure and potential upside for the executive.

Negatives

• The issuance of new stock options, if exercised, could lead to minor dilution for existing shareholders, though this is a standard practice for executive compensation.

Risks

• The value of the stock options is dependent on the future market price of Clene Inc. common stock exceeding the $6.32 exercise price.
• If the company's stock price does not perform well, the options may expire worthless.

Future Outlook

NA

Industry Context

This is a routine insider transaction for executive compensation, common across various industries, particularly in biotechnology and pharmaceutical sectors where long-term incentives are used to retain key scientific talent.

Comparison to Industry Standards

• A Form 4 filing for a single option grant does not provide sufficient data for a detailed comparison to industry benchmarks or specific comparable companies/projects regarding financial results. It is a standard compensation mechanism.

Stakeholder Impact

• Shareholders: Minor potential for future dilution if options are exercised, but also increased alignment of executive interests with shareholder value creation.
• Employees (specifically CSO): Increased personal stake in the company's long-term success and potential for significant personal financial gain if the stock price appreciates.

Key Dates

Keywords

Clene Inc., CLNN, Mark Mortenson, Chief Science Officer, stock options, insider transaction, Form 4, executive compensation, equity grant, 10b5-1 plan